Brief: Vaccinex Announces First Patient Dosed With Anti-Ccr8 Antibody Licensed To Surface Oncology
09/01/2023 13:38
Surface Oncology Inc SURF.O :
* VACCINEX ANNOUNCES FIRST PATIENT DOSED WITH ANTI-CCR8
ANTIBODY
LICENSED TO SURFACE ONCOLOGY
Source text for Eikon: ID:nGNX1936HR
Further company coverage: SURF.O
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease